In these days, primary percutaneous coronary intervention (PCI) is the mainstay for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). However, STEMI patients are more likely to have multi-vessel disease (MVD) and co-morbidities, often leading to frustrated complications such as stent thrombosis even in the 2^nd^ generation drug-eluting stent (DES) era. In this regard, there has been controversy about the clinical benefit of complete revascularization of the non-infarct-related coronary arteries.

There were early observational studies reporting that revascularization of non-infarct-related artery during the primary PCI leads to worse outcomes in MVD and STEMI patients by increasing in-hospital mortality.[@B1]

Promising clinical randomized trials have been reported in DES era, that favors complete revascularization in MVD and STEMI patients. In the Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial[@B2], preventive PCI in non-infarct-related coronary arteries was associated with 65% reduction of cardiovascular death, myocardial infarction (MI) and refractory angina. Complete versus Lesion-only Primary PCI (CvLPRIT) trial[@B3] also demonstrated complete revascularization of non-infarct-related coronary arteries during index admission reduces the composite of death, MI, heart failure, and ischemia-driven revascularization by 55%. Intriguingly, in PRIMULTI trial,[@B4] complete revascularization guided by fractional flow reserve measurements significantly reduced the risk of death, MI, and ischemia-driven revascularization by 44%.

Given these evidences, the American College of Cardiology Foundation/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) guidelines for non-infarct-related artery revascularization in STEMI patients with MVD were modified from an earlier class III indication into class IIb indication.[@B5][@B6] However, most of the previous studies have been conducted using bare metal stent or early generation DES. Therefore, little is known about the efficacy of 2^nd^ generation DES in STEMI patients with MVD. The 2^nd^ generation DES is characterized by improved tissue compatibility and lesser risk of stent thrombosis to enhance a healing process; nowadays recognized as a mainstream treatment modality in coronary artery disease.

In this issue of the *Korean Circulation Journal*, Kwon et al.[@B7] reported the beneficial effect of complete revascularization in STEMI patients with MVD by analyzing the data from the INcheon-Bucheon cohorT of patients undERgoing primary percutaneous coronary intervention for acute ST-ELevation myocardiaL infARction (INTERSTELLAR) registry. They compared the incidence of major adverse cardiac events (MACE) between the MVD patients treated with complete revascularization (n=419) and those treated with culprit-only revascularization (n=286). Complete revascularization of STEMI patients with MVD using the 2^nd^ generation DES was associated with a significant reduction of MACE by 36%. Further, the incidence of cardiovascular death, the hardest endpoint, was also significantly lower in patients treated with complete revascularization (adjusted hazard ratio, 0.57; 95% confidence interval, 0.32--0.97; p=0.03). This finding is consistent with the results of other groups.[@B8]

This study possesses clinical importance since about 25% of patients included for analyses had reduced left ventricular systolic function, which are usually excluded in randomized controlled trials. In conclusion, this study reinforces the usefulness of 2^nd^ generation DES in the treatment of STEMI patients with MVD, thus suggesting the up-to-date treatment strategy. However, previous studies included immediate and staged complete revascularization as a complete revascularization in primary PCI and need to elucidate when immediate complete PCI can be recommended. Furthermore, criteria (anatomical or functional assessment) to intervene for non-culprit lesions should be suggested in future investigations.
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